Steady progress against HER2-positive breast cancer.

作者信息

Hayes Daniel F

出版信息

N Engl J Med. 2011 Oct 6;365(14):1336-8. doi: 10.1056/NEJMe1101326.

DOI:10.1056/NEJMe1101326

PMID:21991956

Abstract

摘要

相似文献

Steady progress against HER2-positive breast cancer.

N Engl J Med. 2011 Oct 6;365(14):1336-8. doi: 10.1056/NEJMe1101326.

ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).

Clin Adv Hematol Oncol. 2003 Apr;1(4):237.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.

[Her2 positive breast cancer: practices].

Bull Cancer. 2011 Feb;98(2):154-63.

Adjuvant trastuzumab in HER2-positive breast cancer.

N Engl J Med. 2012 Feb 16;366(7):664; author reply 664-6. doi: 10.1056/NEJMc1112823.

Adjuvant trastuzumab in HER2-positive breast cancer.

N Engl J Med. 2012 Feb 16;366(7):664; author reply 664-6. doi: 10.1056/NEJMc1112823.

Adjuvant trastuzumab in HER2-positive breast cancer.

N Engl J Med. 2012 Feb 16;366(7):663-4; author reply 664-6. doi: 10.1056/NEJMc1112823.

Adjuvant trastuzumab in HER2-positive breast cancer.

N Engl J Med. 2012 Feb 16;366(7):663; author reply 664-6. doi: 10.1056/NEJMc1112823.

Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.

Oncologist. 2006 May;11(5):533; author reply 534. doi: 10.1634/theoncologist.11-5-533.

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

J Clin Oncol. 2009 Dec 1;27(34):5671-3. doi: 10.1200/JCO.2009.24.2222. Epub 2009 Nov 2.

引用本文的文献

Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study.

Cancers (Basel). 2021 Mar 9;13(5):1166. doi: 10.3390/cancers13051166.

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.

J Natl Cancer Inst. 2021 Jul 1;113(7):808-819. doi: 10.1093/jnci/djaa201.

A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.

Oncotarget. 2015 Jan 20;6(2):1286-301. doi: 10.18632/oncotarget.2676.

Design of clinical trials for biomarker research in oncology.

Clin Investig (Lond). 2011 Dec;1(12):1629-1636. doi: 10.4155/CLI.11.152.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验